Acepodia, Inc. is a clinical-stage biotechnology company specializing in pioneering cell therapies aimed at transforming cancer treatment. The company's primary focus lies in its proprietary Antibody-Cell Conjugation (ACC) platform, a technology that directly links tumor-targeting antibodies to immune cells such as gamma delta 2 T cells, thereby enhancing their efficacy against tumors, including those with low antigen expression. Founded in 2017 by leading scientists from leading research and industry backgrounds, Acepodia has roots in Nobel Prize-winning research on click chemistry. The company advances a pipeline of off-the-shelf cell therapy candidates targeting a range of cancer antigens and is also exploring collaborations in autoimmune disease therapy. With a commitment to scientific innovation and patient-centric solutions, Acepodia is positioned at the intersection of cutting-edge immunology and practical healthcare delivery, aiming to bridge gaps in existing cancer care through next-generation, accessible cellular immunotherapies. Operating within the biotechnology sector, Acepodia plays a significant role in furthering both research and clinical development in oncology and immune system modulation.